News

pharmaphorum2d
Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
pharmaphorum7d
Novartis gets FDA nod for second of three IgAN drugs
Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...
PMLiVE28d
Biogen initiates phase 3 study of felzartamab in kidney transplant patients
The drug was originally developed by MorphoSys, which Novartis also acquired last year. Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy ...
Business Insider1mon
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Biogen plans to initiate Phase 3 trials of felzartamab in IgA nephropathy and primary membranous nephropathy in 2025. Felzartamab was originally developed by MorphoSys AG (now MorphoSys GmbH ...
Pharmabiz28d
Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients
Biogen plans to initiate phase 3 trials of felzartamab in IgA nephropathy and primary membranous nephropathy in 2025. Felzartamab was originally developed by MorphoSys AG (now MorphoSys GmbH, a ...
Taiwan News29d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Biogen plans to initiate Phase 3 trials of felzartamab in IgA nephropathy and primary membranous nephropathy in 2025. Felzartamab was originally developed by MorphoSys AG (now MorphoSys GmbH, a ...